**TABLE 1. Baseline characteristics of patients**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **Patients without cancer**  **(N=903)** | **Patients with cancer in 3 years**  **(N=30)** | **Patients with cancer beyond 3 years**  **(N=29)** | **P Value** |
| **Age (yr)** | 61.1 ± 12.0 | 66.0 ± 11.6 | 62.2 ± 12.3 | 0.083 |
| **Male sex (%)** | 23.5 | 30.0 | 27.6 | 0.632 |
| **Body-mass index (Kg/m2)** | 28.5 ± 4.35 | 27.8 ± 4.71 | 28.8 ± 3.78 | 0.621 |
| **Diabetes (%)** | 24.0 | 16.7 | 31.0 | 0.434 |
| **Present Smoker (%)** | 14.0 | 13.3 | 10.3 | 0.955 |
| **Present or past smoker (%)** | 75.6 | 86.7 | 75.9 | 0.380 |
| **Hypertension (%)** | 63.5 | 80.0 | 72.4 | 0.115 |
| **Previous heart failure (%)** | 12.3 | 3.3 | 0.0 | 0.036 |
| **Peripheral artery disease (%)** | 3.8 | 3.3 | 3.4 | 1.000 |
| **Cerebrovascular events (%)** | 2.9 | 0.0 | 3.4 | 0.660 |
| **Ejection fraction < 40% (%)** | 6.9 | 6.9 | 10.7 | 0.585 |
| **Present or past atrial fibrillation (%)** | 6.0 | 16.7 | 6.9 | 0.064 |
| **MEDICAL THERAPY** |  |  |  |  |
| **Acetylsalicylic acid (%)** | 92.6 | 96.7 | 89.7 | 0.556 |
| **AntiP2Y12 (%)** | 75.7 | 76.7 | 51.7 | 0.013 |
| **Acenocumarol (%)** | 5.2 | 3.3 | 3.4 | 1.000 |
| **Statins (%)** | 94.5 | 93.3 | 93.1 | 0.567 |
| **Oral antidiabetic drugs (%)** | 16.9 | 10.0 | 24.1 | 0.351 |
| **Insulin (%)** | 7.0 | 0.0 | 0.0 | 0.150 |
| **ACEI (%)** | 62.5 | 63.3 | 44.8 | 0.155 |
| **Angiotensin receptor blockers (%)** | 15.0 | 13.3 | 24.1 | 0.370 |
| **Aldosterone receptor blockers (%)** | 7.0 | 6.7 | 3.4 | 0.919 |
| **Betablockers (%)** | 78.8 | 73.3 | 65.5 | 0.184 |
| **Diuretics (%)** | 18.8 | 23.3 | 27.6 | 0.422 |
| **Amiodarone** | 0.9 | 0.0 | 0.0 | 1.000 |
| **Digoxine** | 0.3 | 0.0 | 0.0 | 1.000 |
| **ANALYTICAL DATA** |  |  |  |  |
| **LDL cholesterol (mg/dl)** | 80.5 ± 25.0 | 78.1 ± 25.2 | 85.3 ± 22.5 | 0.518 |
| **HDL cholesterol (mg/dl)** | 42.0 ± 10.8 | 43.4 ± 10.7 | 44.5 ± 13.6 | 0.397 |
| **Non-HDL cholesterol** | 104 ± 30.5 | 98.4 ± 27.1 | 111 ± 28.2 | 0.291 |
| **Triglycerides (mg/dl)** | 101 (66.0) | 92.5 (66.2) | 121 (56.0) | 0.135 |
| **Glycemia (mg/dl)** | 101 (24.0) | 98.0 (17.8) | 99.0 (19.0) | 0.792 |
| **eGFR (CKD-EPI) (ml/min/1.73 m2)** | 78.6 ± 19.4 | 74.4 ± 19.2 | 73.1 ± 17.8 | 0.171 |
| **Hs C-reactive protein (mg/l)** | 1.08 (2.72) | 2.68 (4.63) | 1.49 (2.81) | 0.004 |
| **NT-ProBNP (pg/ml)** | 176 (297) | 272 (815) | 155 (217) | 0.324 |
| **MCP-1 (pg/ml)** | 135 (74) | 151 (58) | 133 (43) | 0.725 |
| **Galectin-3 (ng/ml)** | 7.86 (3.89) | 7.85 (4.13) | 7.50 (2.89) | 0.253 |
| **Hs troponin I (ng/ml)** | 0.003 (0.010) | 0.002 (0.016) | 0.003 (0.009) | 0.837 |
| **Calcidiol (ng/ml)** | 20.4 ± 8.55 | 21.4 ± 9.8 | 17.6 ± 6.93 | 0.175 |

Values are presented as mean±Standard deviation and median (Interquartile range)

# ACEI: Angiotensin-converting inhibitors; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; eGFR: Estimated glomerular filtration rate; HDL: high-density lipoprotein; Hs: High-sensitivity; LDL: low-density lipoprotein MCP-1: monocyte chemoattractant protein-1; NT-Pro-BNP: N-terminal pro-Brain natriuretic peptide.